An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 20, 2025

Primary Completion Date

December 20, 2025

Study Completion Date

December 20, 2027

Conditions

Retinitis Pigmentosa

Interventions

DRUG

IGT001

Study drugs

Trial Locations (1)

RECRUITING

Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER